CND Life Sciences’ Chief Medical Officer and Co-Founder Dr. Todd Levine was awarded a Best Walking Poster Tour Presentation Award for his presentation of results from the Synuclein-One Study at the International Association of Parkinsonism and Related Disorders (IAPRD) World Congress. Dr. Levine’s presentation was selected from a pool of more than 250 posters presented at the May 2023 congress in Chicago.
The Synuclein-One Study examined skin biopsy samples of 343 participants with a clinically confirmed synucleinopathy and healthy controls. The primary outcome was the presence of phosphorylated alpha-synuclein in the skin biopsies of participants compared to clinical diagnosis determined by an investigator and confirmed by an expert panel.
The study demonstrated that the Syn-One Test® detects phosphorylated alpha-synuclein in patients with a suspected synucleinopathy with 95.5% sensitivity and 96.7% specificity,1 making it the most accurate alpha-synuclein biomarker test available.
“Winning this award is further validation of CND’s patient focused mission and the work that we conduct every day. CND is excited to bring this groundbreaking technology to clinicians and patients across the country and would like to thank the investigators and teams from all 30 sites for contributing to this pivotal study,” said Dr. Levine.
Reference:
Gibbons CH, Levine T, Bellaire B, et al. The Synuclein-One Study: skin biopsy detection of phosphorylated alpha-synuclein for diagnosis of synucleinopathies. Neurology. 2023;100(17 suppl 2). 2023 Annual Meeting Abstracts.
